Here are the DEF 14A proxy statements from Claritev Corporation (CTEV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CTEV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTEV filings page.
Claritev Corporation is calling a virtual annual meeting on April 29, 2026 for holders of Class A stock as of March 6, 2026. Stockholders are being asked to elect four Class III directors, ratify PricewaterhouseCoopers LLP as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares under the 2020 Omnibus Incentive Plan.
Claritev positions itself as a healthcare technology, data and insights company focused on transparency and affordability. Management highlights a 2025 “Year of the Turn,” returning to revenue growth, stronger adjusted EBITDA and free cash flow, and more than $67 million in new annual contract value. The company processed $179.8 billion in medical charges, identifying $25.0 billion in potential cost savings, and reports 2025 total stockholder return of 189%.
The executive pay program centers on market-competitive salaries, annual cash incentives and equity awards. 2025 bonuses paid at 110% of target after the leadership team requested negative discretion to shift more of the pool to other employees. From 2026, 25% of long-term incentives for executives will be performance stock units tied to unlevered free cash flow. The proxy also details a classified 11-seat board with a lead independent director, extensive healthcare and technology experience, and committee oversight of risk, including cybersecurity and artificial intelligence, alongside a sustainability working group and plans for a 2025 Corporate Responsibility Report in the third quarter of 2026.